Posts Tagged ‘anti-obesity medicines’

Oh my goodness. Wall Street is having waves of panic about the possibility that big food, big burrito, or big dialysis might not be able to keep selling us ever more of their services and stuff. For the last month we’ve been seeing ripples run through the stock market when investors started thinking maybe consumers […]

We have grown tired of the mindless repetition of a $1,350 monthly list price for Wegovy in endless news reports about the great expense of this very important new drug for obesity. Not because the drug isn’t expensive. But because that list price is not an accurate representation of what the drug really costs. So […]

The week that was OW2023 is history now, leaving us to reflect on what we will remember from this gathering of the top minds in obesity science, clinical care, and health policy. The meeting comes at a pivotal time for obesity care, so we have much to learn from the people who came together here. […]

Forgive us a bit of skepticism please. We are facing a jarring disconnect at ObesityWeek from the reality of medical care that simply can’t keep up with stunning progress in obesity science. Scientists and obesity medicine experts are promising us a tantalizing future for obesity care while the present circumstances facing real people living with […]

We have mixed feelings about a new report in JAMA this week about GLP-1 agonists and the associated risk of gastrointestinal adverse events. On one hand, this is helpful data. It is a reminder that despite all of the sensational reporting about “weight loss miracles,” these drugs are serious medicines that require careful prescribing and […]

At EASD this week, it was quite a showing for tirzepatide. Sold under the brand name Mounjaro, it’s already available for treating diabetes and it’s awaiting approval for treating obesity. Based on the research presented at EASD this week, semaglutide might be looking a little like old news. For tirzepatide, a total of 11 presentations […]

Two professors yesterday at the EASD meeting engaged in a fierce and collegial debate about the feasibility of lasting remission in type 2 diabetes with very low calorie diets. Professor Kamlesh Khunti brought a polished presentation of objective data. He was unequivocal. Is lasting remission feasible in a real world setting? “It’s a definite no […]

It’s enough to make our heads spin. The incredible vibrancy in obesity research is on full display at the meeting of the European Association for the Study of Diabetes – EASD 2023 in Hamburg. Today, it starts with a bang. Successive presentations on multi-agonists for obesity are scheduled this afternoon at EASD. But the abstracts […]

To be sure, we are making progress. Nonetheless, it’s reasonable to ask if we are yet taking the chronic disease of obesity seriously. Or are we just playing at it? Writing in The Lancet, Priya Sumithran, Francis Finucane, and Ricardo Cohen suggest we may still be doing more of the latter: “How we handle obesity […]

Perhaps we should not be surprised. Because the demand for GLP-1 agonists to treat obesity is not the only thing outstripping supply. It seems that the demand for physicians with a certification in obesity medicine is also having a surge. A record number of physicians have applied to take the certification exam this year – […]